{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:24:13Z","timestamp":1787383453389,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005496","name":"American Foundation for Pharmaceutical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009508","name":"Skaggs School of Pharmacy and Pharmaceutical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009508","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40273-026-01624-1","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:34:28Z","timestamp":1780511668000},"page":"1093-1107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4593-179X","authenticated-orcid":false,"given":"Ariel Weiming","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-9458","authenticated-orcid":false,"given":"Mark","family":"Bounthavong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"1624_CR1","unstructured":"Cutrer MF. Pathophysiology, clinical manifestations, and diagnosis of migraine in adults. In: Post T, Swanson JW, Goddeau RP, editors. UpToDate. Wolters Kluwer. https:\/\/www.uptodate.com\/contents\/pathophysiology-clinical-manifestations-and-diagnosis-of-migraine-in-adults. Accessed 1 Feb 2024."},{"key":"1624_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJMra010917","volume":"346","author":"PJ Goadsby","year":"2002","unstructured":"Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med. 2002;346:257\u201370. https:\/\/doi.org\/10.1056\/NEJMra010917.","journal-title":"N Engl J Med"},{"key":"1624_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","volume":"61","author":"R Burch","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60\u20138. https:\/\/doi.org\/10.1111\/head.14024.","journal-title":"Headache"},{"key":"1624_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2.","journal-title":"Lancet"},{"key":"1624_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/00043764-199704000-00009","volume":"39","author":"BS Schwartz","year":"1997","unstructured":"Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med. 1997;39:320\u20137. https:\/\/doi.org\/10.1097\/00043764-199704000-00009.","journal-title":"J Occup Environ Med"},{"key":"1624_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/head.13275","volume":"58","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58:700\u201314. https:\/\/doi.org\/10.1111\/head.13275.","journal-title":"Headache"},{"key":"1624_CR7","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456\u201370. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02223.x.","journal-title":"Headache"},{"key":"1624_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21.","journal-title":"Neurology"},{"key":"1624_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"key":"1624_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-del-Rio M, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24:56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1.","journal-title":"J Headache Pain"},{"key":"1624_CR11","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1705848.","journal-title":"N Engl J Med"},{"key":"1624_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"key":"1624_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, Society TAH. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64:333\u201341. https:\/\/doi.org\/10.1111\/head.14692.","journal-title":"Headache"},{"key":"1624_CR14","unstructured":"U.S. Department of Veterans Affairs. VA National Acquisition Center Contract Catalog Search Tool. https:\/\/www.vendorportal.ecms.va.gov\/nac\/pharma\/list. Accessed 18 Nov 2025."},{"key":"1624_CR15","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337\u201345. https:\/\/doi.org\/10.1212\/WNL.0b013e3182535d20.","journal-title":"Neurology"},{"key":"1624_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01678-y","volume":"24","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Urman R, Gill K, Park AS, Vuvu F, Patel LB, et al. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. J Headache Pain. 2023;24:153. https:\/\/doi.org\/10.1186\/s10194-023-01678-y.","journal-title":"J Headache Pain"},{"key":"1624_CR17","unstructured":"Vtepti (eptinezumab-jjmr) injection. Package insert. Lundbeck Pharmaceuticals LLC. 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=79065861-6aa5-4d1f-829f-3a6471286b36. Accessed 20 Jun 2025."},{"key":"1624_CR18","unstructured":"Aimovig: erenumab-aooe injection. Package insert. Amgen Inc. 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b998ed05-94b0-47fd-b28f-cddd1e128fd8. Accessed 20 Jun 2025."},{"key":"1624_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, Ashina M, Diener H-C, Haghdoost F, Lee MJ, Monteith TS, et al. Setting higher standards for migraine prevention: a position statement of the International Headache Society. Cephalalgia. 2025;45:3331024251320608. https:\/\/doi.org\/10.1177\/03331024251320608.","journal-title":"Cephalalgia"},{"key":"1624_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/head.12997","volume":"57","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache. 2017;57:165\u201378. https:\/\/doi.org\/10.1111\/head.12997.","journal-title":"Headache"},{"key":"1624_CR21","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.clinthera.2020.11.007","volume":"42","author":"TR Smith","year":"2020","unstructured":"Smith TR, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B, et al. Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 Study. Clin Ther. 2020;42:2254-65.e3. https:\/\/doi.org\/10.1016\/j.clinthera.2020.11.007.","journal-title":"Clin Ther"},{"key":"1624_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, et al. Erenumab versus topiramate for the prevention of migraine: a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42:108\u201318. https:\/\/doi.org\/10.1177\/03331024211053571.","journal-title":"Cephalalgia"},{"key":"1624_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneur.61.4.490","volume":"61","author":"SD Silberstein","year":"2004","unstructured":"Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490\u20135. https:\/\/doi.org\/10.1001\/archneur.61.4.490.","journal-title":"Arch Neurol"},{"key":"1624_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/head.14527","volume":"63","author":"Z Ahmed","year":"2023","unstructured":"Ahmed Z, Honomichl R, Thompson SF, Cohen JM, Schuster A, Thompson NR, et al. Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: a retrospective observational study. Headache. 2023;63:908\u201316. https:\/\/doi.org\/10.1111\/head.14527.","journal-title":"Headache"},{"key":"1624_CR25","first-page":"1","volume":"72","author":"E Arias","year":"2023","unstructured":"Arias E, Xu J, Kochanek K. United States life tables, 2021. Natl Vital Stat Rep. 2023;72:1\u201364.","journal-title":"Natl Vital Stat Rep"},{"key":"1624_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1177\/0333102411415879","volume":"31","author":"M Sch\u00fcrks","year":"2011","unstructured":"Sch\u00fcrks M, Rist PM, Shapiro RE, Kurth T. Migraine and mortality: a systematic review and meta-analysis. Cephalalgia. 2011;31:1301\u201314. https:\/\/doi.org\/10.1177\/0333102411415879.","journal-title":"Cephalalgia"},{"key":"1624_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01368-7","volume":"22","author":"M Terhart","year":"2021","unstructured":"Terhart M, Mecklenburg J, Neeb L, Overeem LH, Siebert A, Steinicke M, et al. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain. 2021;22:158. https:\/\/doi.org\/10.1186\/s10194-021-01368-7.","journal-title":"J Headache Pain"},{"key":"1624_CR28","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40273-020-00937-z","volume":"38","author":"R Gidwani","year":"2020","unstructured":"Gidwani R, Russell LB. Estimating transition probabilities from published evidence: a tutorial for decision modelers. Pharmacoeconomics. 2020;38:1153. https:\/\/doi.org\/10.1007\/s40273-020-00937-z.","journal-title":"Pharmacoeconomics"},{"key":"1624_CR29","doi-asserted-by":"publisher","unstructured":"Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, editors. Second Panel on Cost-Effectiveness in Health and Medicine. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 2016. https:\/\/doi.org\/10.1093\/acprof:oso\/9780190492939.002.0007.","DOI":"10.1093\/acprof:oso\/9780190492939.002.0007"},{"key":"1624_CR30","unstructured":"CMS. Search the Physician Fee Schedule. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search?Y=0&T=4&HT=0&CT=3&H1=96365&M=5. Accessed 24 Apr 2026."},{"key":"1624_CR31","first-page":"243","volume":"97","author":"L Mayans","year":"2018","unstructured":"Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97:243\u201351.","journal-title":"Am Fam Physician"},{"key":"1624_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s41669-018-0105-0","volume":"3","author":"JK Porter","year":"2019","unstructured":"Porter JK, Di Tanna GL, Lipton RB, Sapra S, Villa G. Costs of acute headache medication use and productivity losses among patients with migraine: insights from three randomized controlled trials. PharmacoEconomics - Open. 2019;3:411\u20137. https:\/\/doi.org\/10.1007\/s41669-018-0105-0.","journal-title":"PharmacoEconomics - Open"},{"key":"1624_CR33","unstructured":"Medical Expenditure Panel Survey. https:\/\/meps.ahrq.gov\/mepsweb\/. Accessed 4 Sep 2024."},{"key":"1624_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1046\/j.1468-2982.2001.00130.x","volume":"21","author":"G Caro","year":"2001","unstructured":"Caro G, Getsios D, Caro J, Raggio G, Burrows M, Black L. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis. Cephalalgia. 2001;21:12\u20139. https:\/\/doi.org\/10.1046\/j.1468-2982.2001.00130.x.","journal-title":"Cephalalgia"},{"key":"1624_CR35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/14737167.2023.2219898","volume":"23","author":"L J\u00f6nsson","year":"2023","unstructured":"J\u00f6nsson L, Regnier SA, Kymes S, Awad SF, Talon B, Lee XY, et al. Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial. Expert Rev Pharmacoecon Outcomes Res. 2023;23:797\u2013803. https:\/\/doi.org\/10.1080\/14737167.2023.2219898.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1624_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jval.2011.12.007","volume":"15","author":"PJ Gillard","year":"2012","unstructured":"Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health. 2012;15:485\u201394. https:\/\/doi.org\/10.1016\/j.jval.2011.12.007.","journal-title":"Value Health"},{"key":"1624_CR37","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.37765\/ajmc.2025.89822","volume":"31","author":"P Gokhale","year":"2025","unstructured":"Gokhale P, Villa Zapata L. Cost-effectiveness analysis of ubrogepant, rimegepant, and zavegepant for acute migraine treatment vs usual care. Am J Manag Care. 2025;31:e322\u20138. https:\/\/doi.org\/10.37765\/ajmc.2025.89822.","journal-title":"Am J Manag Care"},{"key":"1624_CR38","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0333102418796842","volume":"38","author":"M Sussman","year":"2018","unstructured":"Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018;38:1644\u201357. https:\/\/doi.org\/10.1177\/0333102418796842.","journal-title":"Cephalalgia"},{"key":"1624_CR39","unstructured":"ICER. Migraine: acute & chronic therapies. https:\/\/icer.org\/assessment\/migraine-2018\/. Accessed 21 Mar 2025."},{"key":"1624_CR40","unstructured":"Congressional Budget Office. A comparison of brand-name drug prices among selected federal programs. https:\/\/www.cbo.gov\/publication\/57007. Accessed 27 Mar 2025."},{"key":"1624_CR41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2147\/PPA.S44947","volume":"7","author":"LS Matza","year":"2013","unstructured":"Matza LS, Cong Z, Chung K, Stopeck A, Tonkin K, Brown J, et al. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Prefer Adherence. 2013;7:855\u201365. https:\/\/doi.org\/10.2147\/PPA.S44947.","journal-title":"Patient Prefer Adherence"},{"key":"1624_CR42","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s11136-019-02163-3","volume":"28","author":"LS Matza","year":"2019","unstructured":"Matza LS, Deger KA, Vo P, Maniyar F, Goadsby PJ. Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. Qual Life Res. 2019;28:2359\u201372. https:\/\/doi.org\/10.1007\/s11136-019-02163-3.","journal-title":"Qual Life Res"},{"key":"1624_CR43","unstructured":"Jannsen Pharmaceuticals, Inc. Topamax (topiramate). Package insert. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=21628112-0c47-11df-95b3-498d55d89593. Accessed 20 Nov 2025."},{"key":"1624_CR44","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470\u201385. https:\/\/doi.org\/10.1177\/0333102416678382.","journal-title":"Cephalalgia"},{"key":"1624_CR45","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/PPA.S346660","volume":"16","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study. Patient Prefer Adherence. 2022;16:821\u201339. https:\/\/doi.org\/10.2147\/PPA.S346660.","journal-title":"Patient Prefer Adherence"},{"key":"1624_CR46","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s40122-024-00644-z","volume":"13","author":"R Urman","year":"2024","unstructured":"Urman R, Princic N, Vuvu F, Patel LB, Oh S, Chandler D, et al. Changes in use of migraine medications, healthcare resource utilization, and associated direct costs over 12 months following initiation of erenumab: a US retrospective real-world analysis. Pain Ther. 2024;13:1299\u2013313. https:\/\/doi.org\/10.1007\/s40122-024-00644-z.","journal-title":"Pain Ther"},{"key":"1624_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01636-8","volume":"24","author":"L Charleston","year":"2023","unstructured":"Charleston L, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, et al. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxin A among patients with migraine: a retrospective cohort study. J Headache Pain. 2023;24:101. https:\/\/doi.org\/10.1186\/s10194-023-01636-8.","journal-title":"J Headache Pain"},{"key":"1624_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-024-00813-w","volume":"8","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Awad SF, Rae-Espinoza H, Regnier SA, Lee XY, Goadsby PJ. Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial. J Patient Rep Outcomes. 2024;8:146. https:\/\/doi.org\/10.1186\/s41687-024-00813-w.","journal-title":"J Patient Rep Outcomes"},{"key":"1624_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-025-00711-x","volume":"16","author":"C-S Chan","year":"2025","unstructured":"Chan C-S, Huang T-Y, Tseng W-H, Lin T-K, Yang F-C, Liu Y, et al. Cost-utility analysis of eptinezumab for migraine prevention in Taiwan. Health Econ Rev. 2025;16:11. https:\/\/doi.org\/10.1186\/s13561-025-00711-x.","journal-title":"Health Econ Rev"},{"key":"1624_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01749-8","volume":"25","author":"E Griffin","year":"2024","unstructured":"Griffin E, Shirley G, Lee XY, Awad SF, Tyagi A, Goadsby PJ. An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity. J Headache Pain. 2024;25:59. https:\/\/doi.org\/10.1186\/s10194-024-01749-8.","journal-title":"J Headache Pain"},{"key":"1624_CR51","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40273-024-01380-0","volume":"42","author":"T Takeshima","year":"2024","unstructured":"Takeshima T, Sakai F, Wang X, Yamato K, Kojima Y, Zhang Y, et al. Cost effectiveness of fremanezumab in episodic and chronic migraine patients from a Japanese healthcare perspective. Pharmacoeconomics. 2024;42:811\u201322. https:\/\/doi.org\/10.1007\/s40273-024-01380-0.","journal-title":"Pharmacoeconomics"},{"key":"1624_CR52","unstructured":"Canadian Agency for Drugs and Technologies in Health. Galcanezumab (Emgality): CADTH reimbursement review: therapeutic area: prevention of migraine. Pharmacoeconomic review. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK596659\/. Accessed 30 Apr 2026."},{"key":"1624_CR53","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs. 2021;35:805\u201320. https:\/\/doi.org\/10.1007\/s40263-021-00834-9.","journal-title":"CNS Drugs"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01624-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01624-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01624-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:41:03Z","timestamp":1787380863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01624-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01624-1","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ariel Weiming Dong has no conflict of interest during manuscript preparation. However, Ariel Weiming Dong will start a fellowship with one of the manufacturers of erenumab. The manufacturer had no role in the study design, analysis, interpretation, or reporting of results. Mark Bounthavong has received consulting fees from Merck & Co. for unrelated projects.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve patient-level data and human participants. No ethics approval was needed.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data used in this study were obtained from the published literature and publicly available sources. No new data were generated or analyzed in this study.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code used to perform the analysis is included in the ESM. This cost-utility analysis is open source. A link to the repository is available upon request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: AD, MB. Methodology: AD, MB. Formal analysis and investigation: AD, MB; writing (original draft preparation): AD. Writing (review and editing): AD, MB. Supervision: MB. Both authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}